Obsidian Therapeutics, Inc. Common Stock OBX
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $39.00 (+181.3% upside)
Key Stats
- Today's Range
- $9.71 – $14.77
- 50-Day Range
- $9.60 – $19.96
- 52-Week Range
- $9.60 – $49.97
- Volume
- 2.09 million shs
- Average Volume
- 447K shs
- Market Cap
- $593.02 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.06%
- Days to Cover
- 1.00
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
Related Stocks
Compare head-to-head: OBX vs LLY·OBX vs JNJ·OBX vs ABBV·OBX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.